DSpace Repository

Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions

Show simple item record

dc.contributor.author Vart, P.
dc.contributor.author Correa-Rotter, R.
dc.contributor.author Hou, F.F.
dc.contributor.author Jongs, N.
dc.contributor.author Chertow, G.M.
dc.contributor.author Langkilde, A.M.
dc.contributor.author McMurray, J.J.V.
dc.contributor.author Rossing, P.
dc.contributor.author Sjöström, C.D.
dc.contributor.author Stefansson, B.V.
dc.contributor.author Toto, R.D.
dc.contributor.author Douthat, W.
dc.contributor.author Escudero, E.
dc.contributor.author Isidto, R.
dc.contributor.author Khullar, D.
dc.contributor.author Bajaj, H.S.
dc.contributor.author Wheeler, D.C.
dc.contributor.author Heerspink, H.J.L.
dc.date.accessioned 2022-06-01T13:53:57Z
dc.date.available 2022-06-01T13:53:57Z
dc.date.issued 2022
dc.identifier.uri https://hdl.handle.net/20.500.12866/11732
dc.description.abstract Introduction: This study aimed to examine the efficacy and safety of dapagliflozin in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (NCT03036150) by geographic region. Methods: Adults with chronic kidney disease (CKD) with or without type 2 diabetes, with estimated glomerular filtration rate (eGFR) 25 to 75 ml/min per 1.73 m2 and urinary albumin-to-creatinine ratio (UACR) 200 to 5000 mg/g were randomized to dapagliflozin (10 mg once daily) or placebo. The primary end point was a composite of a sustained decline in eGFR of ≥50%, end-stage kidney disease or death from kidney or cardiovascular causes. We categorized recruiting countries into 4 broad global regions: Asia, Europe, Latin America, and North America. Of 4304 randomized patients, 1346 (31.3%) were from Asia, 1233 (28.6%) from Europe, 912 (21.2%) from Latin America, and 813 (18.9%) from North America. Results: The relative risk of the primary composite end point was lower in patients randomized to dapagliflozin (relative to placebo) in all regions, with hazard ratios (95% CI) of 0.70 (0.48–1.00), 0.60 (0.43–0.85), 0.61 (0.43–0.86), and 0.51 (0.34–0.76) among patients from Asia, Europe, Latin America, and North America, respectively. There was no effect modification by region (interaction P = 0.77). Occurrence of serious adverse events (SAEs) was lower among patients randomized to dapagliflozin versus placebo (21.9% vs. 26.8%, 34.1% vs. 38.6%, 29.8% vs. 31.5%, and 34.9% vs. 41.0% in Asia, Europe, Latin America, and North America, respectively). Conclusion: Dapagliflozin reduced kidney and cardiovascular events and prolonged survival in patients with CKD, with and without type 2 diabetes, with no apparent effect modification by geographic region. en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartofseries Kidney International Reports
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject dapagliflozin en_US
dc.subject efficacy en_US
dc.subject regions en_US
dc.subject safety en_US
dc.subject SGLT-2 inhibitor en_US
dc.title Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/j.ekir.2022.01.1060
dc.relation.issn 2468-0249


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics